Trium Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Trium Capital’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-102,105	Closed	-$13.5M	–	75
2025 Q1	$13.5M	Buy	+102,105	New	+$12.7M	1.68%	9

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Trium Capital's ITCI Position: Q2 2025 in Review

Trium Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 102,105 shares — an estimated $13.5M sold.

Trium Capital first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $13.5M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Trium Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Trium Capital sold 102,105 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $13.5M.
Trium Capital first reported a position in Intra-Cellular Therapies Inc. in Q1 2025 and held it in 1 quarter.
Trium Capital's Intra-Cellular Therapies Inc. position peaked at $13.5M in Q1 2025.
3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Trium Capital's 13F filing for Q2 2025, filed 11 Aug 2025.